Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

COVID-19

ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Ivermectin

Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Placebo

Stromectol. FDA Approved Package Insert 2009

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

The subject is considered to have progressed to severe illness when one or more of the following criteria are present:
Breathing difficulty (≥30 breaths per minute);
Resting oxygen saturation ≤93%;
Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
AND
Imigrane infusion (0.4 mg/min) for 10 mins

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
AND
Isotonic saline for 10 mins (placebo)

Rosacea

All patients will undergo this intervention on one of two study days

Imigran

Isotonic Saline

DanishHC

PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea

Investigation of PACAP38-induced Headache and Rosacea-like Symptoms in Patients With Rosacea

Incidence of PACAP38-induced headache and migraine-like attacks in patients with rosacea measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable") and international classification for migraine.

Severity of PACAP38-induced headache after pretreatment with sumatriptan in rosacea patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")

Severity of PACAP38-induced flushing with and without sumatriptan-treatment measured by laser doppler flowmetry

PACAP38-induced temperature changes with and without sumatriptan-treatment measured by infrared thermography

Superficial temporal artery diameter after PACAP38 with and without sumatriptan-treatment measured by ultrasound

Nita Katarina Frifelt Wienholtz

Principal Investigator, Medical Doctor, PhD Student

Danish Headache Center

Papulopustular Rosacea

Once daily administration of BPX-04 minocycline gel for 12 weeks

minocycline topical gel

Once daily administration of BPX-04 gel vehicle for 12 weeks

topical gel vehicle

Study Center

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea

Change in mean facial inflammatory lesion count

Proportion of subjects with ≥2-point change in IGA of rosacea to clear or almost clear

BioPharmX, Inc.

Vehicle control is identical to the active product in appearance

Nasal Breathing

MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge

The Efficacy of the MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge A Randomized, Double-blind, Adaptive-design Study

rosacea/sakit kepala

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge

Database tanaman obat terlengkap yang didukung oleh sains